Vol 31, No 3 (2024)
Review Article
Published online: 2024-05-21
Influence of xanthine oxidase inhibitors on all-cause mortality in adults: a systematic review and meta-analysis
Abstract
Xanthine oxidase inhibitors, including allopurinol and febuxostat, are the first-line treatment of hyperuricemia. This meta-analysis investigated the association between urate-lowering therapy and all-cause mortality in different chronic diseases to match its users and non-users in a real-world setting. Overall, 11 studies were included, which reported adjusted hazard ratios for all-cause mortality over at least 12 months. Meta-analysis of all included studies showed no effect of the therapy on all-cause mortality. However, subgroup analyses showed its beneficial effect in patients with chronic kidney disease (14% risk reduction) and hyperuricemia (14% risk reduction), but not in patients with heart failure (28% risk increase). Urate-lowering therapy reduces all-cause mortality among patients with hyperuricemia and chronic kidney disease, but it seems to increase mortality in patients with heart failure and should be avoided in this subgroup
Keywords: all-cause mortalityallopurinolfebuxostathyperuricemiaxanthine oxidase inhibitors
References
- Chen-Xu M, Yokose C, Rai SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6): 991–999.
- Mikuls T. Gout. New England Journal of Medicine. 2022; 387(20): 1877–1887.
- Salem CB, Slim R, Fathallah N, et al. Drug-induced hyperuricaemia and gout. Rheumatology. 2016: kew293.
- Neeley WL, Essigmann JM. Mechanisms of formation, genotoxicity, and mutation of guanine oxidation products. Chem Res Toxicol. 2006; 19(4): 491–505.
- Pang Bo, McFaline JL, Burgis NE, et al. Defects in purine nucleotide metabolism lead to substantial incorporation of xanthine and hypoxanthine into DNA and RNA. Proc Natl Acad Sci U S A. 2012; 109(7): 2319–2324.
- Yang HC, Nguyen PA, Islam M, et al. Gout drugs use and risk of cancer: A case-control study. Joint Bone Spine. 2018; 85(6): 747–753.
- Cho SK, Chang Y, Kim I, et al. U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study. Arthritis Rheumatol. 2018; 70(7): 1122–1132.
- Lee SY, Park W, Suh YJu, et al. Association of Serum Uric Acid with Cardiovascular Disease Risk Scores in Koreans. Int J Environ Res Public Health. 2019; 16(23): 4632.
- Ramos GK, Goldfarb DS. Update on Uric Acid and the Kidney. Curr Rheumatol Rep. 2022; 24(5): 132–138.
- Moher D, Shamseer L, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1): 1.
- Lo CKL, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014; 14: 45.
- Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011; 343: d2090.
- IntHout J, Ioannidis JPA, Rovers MM, et al. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016; 6(7): e010247.
- Baujat B, Mahé C, Pignon JP, et al. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002; 21(18): 2641–2652.
- Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629–634.
- Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019; 22(4): 153–160.
- Harrer M, Cuijpers P, Furukawa T, Ebert DD. Doing Meta-Analysis with R, A Hands-On Guide. Chapman and Hall/CRC, New York 2021.
- Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015; 74(7): 1368–1372.
- Hung PH, Lin CH, Hung KY, et al. Clinical burden of autosomal dominant polycystic kidney disease. Aging (Albany NY). 2020; 12(4): 3899–3910.
- Ju C, Lai RW, Li KaH, et al. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology (Oxford). 2020; 59(9): 2340–2349.
- Kuo CF, Grainge MJ, Mallen C, et al. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis. Rheumatology (Oxford). 2015; 54(12): 2145–2150.
- Larsen KS, Pottegård A, Lindegaard HM, et al. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. Am J Med. 2016; 129(3): 299–306.e2.
- Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009; 48(7): 804–806.
- Tsuruta Y, Nitta K, Akizawa T, et al. Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS. Int Urol Nephrol. 2014; 46(9): 1833–1841.
- Watanabe K, Nakayama M, Yamamoto T, et al. Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study. PLoS One. 2021; 16(3): e0249240.
- Wei J, Choi HK, Neogi T, et al. Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study. Ann Intern Med. 2022; 175(4): 461–470.
- Wei L, Fahey T, Struthers AD, et al. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract. 2009; 63(9): 1327–1333.
- Weisman A, Tomlinson GA, Lipscombe LL, et al. Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. Can J Diabetes. 2021; 45(7): 641–649.e4.
- Mackenzie I, Hawkey C, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022; 400(10359): 1195–1205.
- Kanbay M, Afsar B, Siriopol D, et al. Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. Angiology. 2020; 71(4): 315–323.
- Tamariz L, Hare JM. Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation. 2015; 131(20): 1741–1744.
- Mackenzie IS, Hawkey CJ, Ford I, et al. ALL-HEART Study Group. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022; 400(10359): 1195–1205.
- Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021; 28(1): 1–14.
- Ejaz AA, Nakagawa T, Kanbay M, et al. Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage. Semin Nephrol. 2020; 40(6): 574–585.
- Agborbesong E, Li LX, Li Lu, et al. Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD. Front Mol Biosci. 2022; 9: 922428.
- Park HC, Kang AY, Jang JY, et al. Chronic asymptomatic pyuria precedes overt urinary tract infection and deterioration of renal function in autosomal dominant polycystic kidney disease. BMC Nephrol. 2013; 14: 1.
